rethinkTHC Search
Menu
Study breakdown

Could Cannabis Be a Treatment for Autoimmune Diseases?

Narrative ReviewModerate evidence
The takeaway

Cannabis compounds act as immune modulators that reduce inflammation, and clinical trials suggest effectiveness in multiple sclerosis, IBD, and fibromyalgia, though large-scale evidence is lacking.

Read this if you have an autoimmune condition and want to understand the scientific basis for cannabis as a potential treatment.

Cannabis compounds reduce pro-inflammatory and increase anti-inflammatory cytokines

What the researchers found

This review examined cannabis and its active compounds as potential treatments for autoimmune diseases, conditions where the immune system mistakenly attacks the body's own tissues.

The evidence supports cannabinoids as immune-modulating agents that affect T-cells, B-cells, monocytes, and microglia cells. The overall effect is a reduction in pro-inflammatory cytokines and an increase in anti-inflammatory cytokines, which is the opposite of what occurs in autoimmune diseases.

Clinical trials have already suggested effectiveness in three autoimmune conditions: multiple sclerosis (spasticity and pain), inflammatory bowel disease, and fibromyalgia. However, contradicting results and the lack of large-scale trials make these findings inconclusive.

Laboratory and animal studies also show correlations between disease activity and cannabinoids in rheumatoid arthritis, type 1 diabetes, and systemic sclerosis, though these have not yet progressed to clinical trials.

Why it matters

Autoimmune diseases affect roughly 5-8% of the population and current treatments often carry significant side effects. If cannabinoids can modulate immune function with fewer side effects, they could complement or replace existing therapies for millions of patients.

The numbers in context

Clinical trial evidence exists for three conditions: multiple sclerosis, inflammatory bowel disease, and fibromyalgia. Preclinical evidence exists for rheumatoid arthritis, type 1 diabetes, and systemic sclerosis.

How the study worked

Narrative review of evidence on cannabinoids and autoimmunity, covering immune cell effects, clinical trials in MS/IBD/fibromyalgia, and preclinical data on rheumatoid arthritis, type 1 diabetes, and systemic sclerosis.

What this study cannot tell us

Narrative review without systematic methodology. Clinical evidence remains limited to small trials with sometimes contradicting results. The leap from immune modulation in the lab to clinical benefit in patients is not always straightforward.

How to read the evidence

Narrative review covering clinical and preclinical evidence. Moderate because some clinical trial data exists but large-scale confirmation is lacking.

When this study was published

Published in 2017.

The bigger picture

The immune-modulating properties of cannabinoids connect two rapidly growing fields: autoimmune disease research and cannabinoid medicine. This convergence suggests cannabinoids may have therapeutic applications far beyond pain and nausea, potentially addressing the underlying immune dysfunction in autoimmune conditions.

Questions still open

  • Could CBD alone (without THC) provide autoimmune benefits? Would cannabinoid therapy work better as a complement to existing immunosuppressants or as a replacement? Which autoimmune conditions are most likely to benefit from cannabinoid treatment?

Common questions

Can cannabis help autoimmune diseases?
Laboratory evidence shows cannabinoids modulate immune function in ways that could benefit autoimmune conditions. Small clinical trials suggest effectiveness in MS, IBD, and fibromyalgia, but large-scale evidence is still needed.
Which autoimmune conditions might benefit from cannabis?
Clinical trials have shown promise for multiple sclerosis, inflammatory bowel disease, and fibromyalgia. Preclinical data also suggest potential for rheumatoid arthritis, type 1 diabetes, and systemic sclerosis.

Read the original research

Medical cannabis: Another piece in the mosaic of autoimmunity?

Clinical pharmacology and therapeutics, 101(2), 230-238

Citation

Katz, D; Katz, I; Porat-Katz, B S; Shoenfeld, Y. (2017). Medical cannabis: Another piece in the mosaic of autoimmunity?. Clinical pharmacology and therapeutics, 101(2), 230-238. https://doi.org/10.1002/cpt.568

Explore the wider topic